Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.940 +0.100 (+5.43%)

Delayed Quote Updated: 4:00 PM EST, Nov 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗

August 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

Did You See What Cathie Wood Bought on Wednesday? ↗

July 22, 2021

ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.

Via The Motley Fool

Unusual Options Activity Insight: Fate Therapeutics ↗

July 12, 2021

On Monday, shares of Fate Therapeutics (NASDAQ:FATE) saw unusual options activity. After the option alert, the stock price moved down to $88. Sentiment: BEARISH Option Type:...

Via Benzinga

Elliott Wave Technical Analysis For Six US Stocks - CDNA, CRWD, FATE, UPS, HDB, SPOT ↗

July 03, 2021

CareDx, CrowdStrike, Fate Therapeutics, HDFC Bank, Spotify, UPS - Daily charts.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2021 ↗

June 07, 2021

Upgrades Deutsche Bank upgraded the previous rating for Marriott Vacations Worldwide Corp (NYSE:VAC) from Hold to Buy. Marriott Vacations earned $0.49 in the first quarter...

Via Benzinga

Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21 ↗

June 04, 2021

Fate Therapeutics Inc (NASDAQ: FATE) has revealed some new data from an ongoing Phase 1 trial evaluating FT516 for patients with relapsed / refractory B-cell...

Via Benzinga

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients ↗

May 14, 2021

Fate Therapeutics Inc (NASDAQ: FATE) has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 13, 2021

Gainers Bionano Genomics (NASDAQ:BNGO) st...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use ↗

May 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc...

Via Benzinga

Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat ↗

May 12, 2021

Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics...

Via Benzinga

Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com ↗

May 09, 2021

Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc (NASDAQ: JD), a key rival to Alibaba Group Holding (NYSE: BABA...

Via Benzinga

Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings ↗

May 10, 2021

Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ:

Via Benzinga

Fate Therapeutics Inc (FATE) Q1 2021 Earnings Call Transcript ↗

May 06, 2021

FATE earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Preview: Fate Therapeutics's Earnings ↗

May 04, 2021

On Wednesday, May 05, Fate Therapeutics (NASDAQ:FATE) will release its latest earnings report. Benzinga's outlook for Fate Therapeutics is included in the following report. Net...

Via Benzinga

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know ↗

May 07, 2021

Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday. ARKF shed 298,505 Apple...

Via Benzinga

Cathie Wood Buys Yet Another Workhorse Dip, Also Adds DraftKings, Peloton, Square ↗

April 13, 2021

Cathie Wood-led Ark Investment Management on Monday bought in more shares of the electric vehicle company Workhorse Group Inc (NASDAQ: WKHS) on a day the stock fell about 6% to $...

Via Benzinga

Topics Electric Vehicles

LendingTree, Trimble, ICE, Fate Therapeutics — What Cathy Wood's Ark Bought And Sold On Tuesday ↗

April 06, 2021

Cathie Wood’s Ark Investment Management sends out an email every night listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.